2-trifluoromethoxyanisole | 16222-38-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-trifluoromethoxyanisole
• 英文别名: tert-Butyl 2-methoxyphenyl ether；1-methoxy-2-[(2-methylpropan-2-yl)oxy]benzene
• CAS: 16222-38-1
• 化学式: C₁₁H₁₆O₂
• 分子量: 180.247
• InChiKey: ZNBPFNPUNMLSMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-trifluoromethoxyanisole 在 sodium nitrate 作用下， 以 三氟乙酸 为溶剂， 反应 4.0h， 以73%的产率得到1-methoxy-4-nitro-2-(trifluoromethoxy)benzene
  参考文献：
  名称：

  [EN] N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY
  [FR] DERIVES DE N-HYDROXYAMIDE AYANT UNE ACTIVITE ANTI-BACTERIENNE

  摘要：

  公开号：

  WO2004007444A3
• 作为产物：
  描述：

  叔丁基邻苯二酚 生成 2-trifluoromethoxyanisole
  参考文献：
  名称：

  DOI, MIKIHARU;MATSUI, MUNEAKI;SHUTO, YOSHIHIRO;KINOSHITA, YOSHIRO, AGR. AND BIOL. CHEM., 54,(1990) N0, C. 2753-2754

  摘要：

  DOI：

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS
  申请人：Kandula Mahesh

  公开号：US20150133407A1

  公开（公告）日：2015-05-14

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of viscid or excessive mucus, cough, inflammation, redness in sore throat, infection in the throat, sore throat, abnormal mucus secretion, impaired mucus transport, allergic rhinitis, asthma, COPD, respiratory muscular disorders and pain in acute sore throat.

  本发明涉及公式I的化合物或其药用可接受的盐，以及它们的聚合物、溶剂化物、对映体、立体异构体和水合物。包含有效量的公式I化合物的药物组合物，以及用于治疗呼吸系统疾病的方法，可以口服、颊部、直肠、局部、经皮、经粘膜、静脉、非肠道给药、糖浆或注射剂的形式制备。此类组合物可用于治疗粘性或过量粘液、咳嗽、喉咙痛的红肿、喉咙感染、喉咙痛、异常粘液分泌、粘液运输受损、过敏性鼻炎、哮喘、慢性阻塞性肺病（COPD）、呼吸肌疾病和急性喉咙痛的疼痛。
• P38 kinase inhibiting agents
  申请人：Chen Meng-Hsin

  公开号：US20070129372A1

  公开（公告）日：2007-06-07

  Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

  化学式（I）描述的化合物或其药用盐：是p38的抑制剂，可用于治疗炎症，如治疗类风湿关节炎、类风湿脊柱炎、骨关节炎、痛风性关节炎和其他关节炎症状；发炎关节、湿疹、牛皮癣或其他炎症性皮肤病症，如晒伤；包括结膜炎在内的炎症性眼部疾病；发热、疼痛和其他与炎症相关的病症。
• Peptidomimetics and Methods of Using the Same
  申请人：The Regents of the University of Michigan

  公开号：US20180072677A1

  公开（公告）日：2018-03-15

  Disclosed herein are compounds useful for modulating the mu-opioid receptor (“MOR”) and/or delta-opioid receptor (“DOR”), and methods of using these compounds to treat diseases and conditions, such as pain. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: wherein the substituents are as described.

  本文披露了一些有用于调节μ-阿片受体（“MOR”）和/或δ-阿片受体（“DOR”）的化合物，以及使用这些化合物治疗疾病和病况（如疼痛）的方法。具体来说，本文披露了一些符合下列式（I）的化合物及其药用可接受的盐：其中取代基如所述。
• SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：BARTH Francis

  公开号：US20100041709A1

  公开（公告）日：2010-02-18

  The present invention relates to compounds corresponding to formula (I): Wherein X, R 1 , R 2 , R 3 and R 4 are as defined herein. The invention further relates to preparation and therapeutic use of these compounds.

  本发明涉及与以下化学式（I）对应的化合物：其中X、R1、R2、R3和R4如本文所定义。该发明还涉及这些化合物的制备和治疗用途。
• COMPOSITIONS AND METHODS FOR THE TREATMENT ANGINA AND CARDIOVASCULAR CONDITIONS
  申请人：Cellixbio Private Limited

  公开号：US20150148352A1

  公开（公告）日：2015-05-28

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of angina and cardiovascular conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic aneurysm, angina, atherosclerosis, cerebrovascular accident (stroke), cerebrovascular disease, congestive heart failure, coronary artery disease, myocardial infarction (heart attack), peripheral vascular disease, aortic dissection, aortic stenosis, arrhythmia (irregular heartbeat), atrial fibrillation, cardiomyopathy, chest pain, claudication, congenital heart disease.

  本发明涉及公式I化合物或其药学上可接受的盐，以及其多晶形、溶剂化合物、对映体、立体异构体和水合物。该药物组合物包括有效量的公式I化合物，并可制备用于口服、颊下、直肠、局部、经皮、经黏膜、静脉、肌肉注射、糖浆或注射的药物组合物，用于治疗心绞痛和心血管疾病的方法。这些组合物可用于治疗慢性动脉瘤、心绞痛、动脉粥样硬化、脑血管意外（中风）、脑血管疾病、充血性心力衰竭、冠状动脉疾病、心肌梗死（心脏病发作）、周围血管疾病、主动脉夹层、主动脉瓣狭窄、心律失常（心跳不规则）、心房颤动、心肌病、胸痛、跛行、先天性心脏病。